Table 3. Adverse events (AE) reported in the studies in contacts of MDR-TB patients.

Treatment	Number of serious AEa	Number of AE that were reason for dropout	Adverse events
PYRAZINAMIDE+ETHAMBUTOL
Younossian, 2005 [29]	0/12	7/12 (58%)	7/12 (58%) discontinued because of increase in ASAT or ALAT (n = 6) or mild elevation of liver enzymes associated with gastrointestinal symptoms. Symptoms: nausea (2/12); vomiting (1/12); loss of appetite (1/12); dizziness (1/12); visual disturbances with normal VEP (1/12); increased ALAT or ASAT (5/12).
PYRAZINAMIDE+LEVOFLOXACIN
Papastavros, 2002 [28]	0/12	17/17 (100%)	17/17 (100%) experienced at least one abnormal symptom or sign and both drugs were discontinued in all patients. Profiles: gastrointestinal disorders (9/17); nervous system disorders (8/17); hyperuricemia (uric acid+urate level>upper limit of normal) (8/17); elevated liver enzymes (8/17); dermatological (5/17); musculoskeletal disorders (14/17).
PYRAZINAMIDE+OFLOXACIN
Horn, 1994 [12]	NR	14/16 (88%)	13/17 had one or more adverse effects: gastrointestinal distress (6/16); insomnia (3/16); vertigo (2/16); arthralgia (7/16); hepatitis requiring treatment (4/16); pruritus (4/16); fatigue (4/16); rash (3/16); increased ALAT levels (4/16). Previous use of INH may have contributed to development of hepatitis.
Ridzon, 1997 [13]	3/22	13/22 (59%)	Medications were stopped for 13 contacts: 7/13 had mild to moderate increases in serum aminotransferase levels. Adverse events: nausea (3/22); diarrhea (1/22); persistent vomiting (1/22); lost appetite (1/22); angioedema (1/22*); arthralgia (2/22); itching (2/22); fatigue (1/22); sour taste in mouth (1/22); feeling hot and tingling (1/22); elevated ASAT/ALAT (mild: 9/22, significant: 2/22*)). * serious adverse events

^aas reported by authors.